BioCryst Pharmaceuticals 미래 성장

Future 기준 확인 4/6

BioCryst Pharmaceuticals은 연간 수입과 매출이 각각 72.8%와 15.3% 증가할 것으로 예상되고 EPS는 연간 72.6%만큼 증가할 것으로 예상됩니다.

주요 정보

72.8%

수익 성장률

72.6%

EPS 성장률

Biotechs 수익 성장	0%
매출 성장률	15.3%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	19 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

BMV:BCRX * - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	625	74	170	N/A	8
12/31/2025	534	-14	93	46	10
12/31/2024	446	-78	5	-52	9
9/30/2024	413	-124	-57	-56	N/A
6/30/2024	382	-146	-86	-84	N/A
3/31/2024	355	-209	-104	-101	N/A
12/31/2023	331	-227	-97	-95	N/A
9/30/2023	318	-236	-112	-110	N/A
6/30/2023	307	-243	-124	-123	N/A
3/31/2023	290	-226	-133	-132	N/A
12/31/2022	271	-247	-163	-162	N/A
9/30/2022	238	-193	-172	-170	N/A
6/30/2022	204	-210	-163	-161	N/A
3/31/2022	188	-194	-162	-159	N/A
12/31/2021	157	-184	-145	-142	N/A
9/30/2021	114	-227	-154	-152	N/A
6/30/2021	79	-214	-168	-167	N/A
3/31/2021	32	-209	-173	-173	N/A
12/31/2020	18	-183	-136	-135	N/A
9/30/2020	54	-125	-103	-103	N/A
6/30/2020	49	-116	-93	-92	N/A
3/31/2020	48	-115	-86	-86	N/A
12/31/2019	49	-109	-90	-90	N/A
9/30/2019	12	-134	-103	-103	N/A
6/30/2019	12	-126	-111	-111	N/A
3/31/2019	23	-107	-100	-100	N/A
12/31/2018	21	-101	-93	-93	N/A
9/30/2018	22	-93	-79	-79	N/A
6/30/2018	29	-79	N/A	-56	N/A
3/31/2018	20	-77	N/A	-52	N/A
12/31/2017	25	-66	N/A	-41	N/A
9/30/2017	30	-51	N/A	-36	N/A
6/30/2017	29	-47	N/A	-42	N/A
3/31/2017	31	-47	N/A	-43	N/A
12/31/2016	26	-55	N/A	-53	N/A
9/30/2016	22	-69	N/A	-62	N/A
6/30/2016	25	-72	N/A	-58	N/A
3/31/2016	46	-51	N/A	-28	N/A
12/31/2015	48	-43	N/A	-13	N/A
9/30/2015	49	-37	N/A	-12	N/A
6/30/2015	41	-31	N/A	-8	N/A
3/31/2015	17	-50	N/A	-33	N/A
12/31/2014	14	-45	N/A	-39	N/A
9/30/2014	19	-39	N/A	-29	N/A
6/30/2014	18	-38	N/A	-28	N/A
3/31/2014	17	-36	N/A	-24	N/A
12/31/2013	17	-30	N/A	-27	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BCRX * 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 8.1% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: BCRX * (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: BCRX * 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: BCRX * 의 수익(연간 15.3% ) MX 시장( 7.2% 보다 빠르게 성장할 것으로 예상됩니다. 7.2% 연간).

고성장 수익: BCRX * 의 수익(연간 15.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BCRX * 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/26 21:49
장 마감 주가	2024/11/11 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

BioCryst Pharmaceuticals, Inc. 30 애널리스트 중 10 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Huidong Wang	Barclays
Tazeen Ahmad	BofA Global Research
Dae Gon Ha	BTIG

BioCryst Pharmaceuticals 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2026

Recent updates

BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland

Insufficient new directors

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022)

Forecast to breakeven in 2026

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Forecast to breakeven in 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022)

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

High number of new directors

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic

Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

High number of new directors

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

High number of new directors

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022